PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States ...

In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential total ...

Derick Giwner serves as Editor of DRF Harness for Daily Racing Form. He has worked for Sports Eye/Harness Eye since 1996 and has served as editor of the paper since 2005. He has worn many hats in the ...